Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Chemiphar CoTSE:4539 -0.26%50 Debt-to-EBITDA is 2.35 as of Mar. 2026, which is 66% below its 10-year median of 7.00. GuruFocus rates TSE:4539 with a GF Score™ of 50/100 and a GF Value™ of 円1,710.48 (Fairly Valued). The stock has 6 warning signs investors should review. Among 685 Drug Manufacturers companies, Nippon Chemiphar Co ranks worse than 90.22% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nippon Chemiphar Co's Debt-to-EBITDA or its related term are showing as below:
TSE:4539'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.7 Med: 7 Max: 12.07
Current: 8.27
During the past 13 years, the highest Debt-to-EBITDA Ratio of Nippon Chemiphar Co was 12.07. The lowest was 3.70. And the median was 7.00.
TSE:4539's Debt-to-EBITDA is ranked worse than 90.22% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs TSE:4539: 8.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nippon Chemiphar Co Debt-to-EBITDA Related Terms
Nippon Chemiphar Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nippon Chemiphar Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Chemiphar Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Chemiphar Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Chemiphar Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nippon Chemiphar Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Nippon Chemiphar Co (TSE:4539) has a Debt-to-EBITDA of 2.35 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nippon Chemiphar Co. This is 66% below median its historical median of 7.00. Over the past decade, Nippon Chemiphar Co's Debt-to-EBITDA has ranged from 3.70 to 12.07. According to the industry distribution chart, Nippon Chemiphar Co ranks #618 out of 685 companies in the Drug Manufacturers industry, placing it in the top 90.2%.
Is Nippon Chemiphar Co's Debt-to-EBITDA too high?
Nippon Chemiphar Co's current Debt-to-EBITDA of 2.35 is 66% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 12.07. The Drug Manufacturers industry median Debt-to-EBITDA is 1.58. Nippon Chemiphar Co's value of 2.35 is 48.7% above this industry median. Based on the distribution chart, Nippon Chemiphar Co ranks #618 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nippon Chemiphar Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nippon Chemiphar Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Chemiphar Co ranks #618 out of 685 companies for Debt-to-EBITDA. This places Nippon Chemiphar Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.58. Nippon Chemiphar Co's value of 2.35 is 48.7% above this benchmark. Historically, Nippon Chemiphar Co's own Debt-to-EBITDA has ranged from 3.70 to 12.07 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 1.58, Nippon Chemiphar Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Chemiphar Co's current Debt-to-EBITDA of 2.35 is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nippon Chemiphar Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Chemiphar Co's current Debt-to-EBITDA is 2.35, which is 66% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Chemiphar Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Chemiphar Co (TSE:4539) is currently considered Fairly Valued. The stock's GF Value™ is 円1,710.48, compared to a current price of 円1,564.00 — trading 8.6% below its estimated fair value. The current Debt-to-EBITDA is 2.35, which is 66% below median its 10-year median of 7.00 and 48.7% above the Drug Manufacturers industry median of 1.58. Nippon Chemiphar Co's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nippon Chemiphar Co (TSE:4539), the current Debt-to-EBITDA is 2.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Chemiphar Co (TSE:4539) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Chemiphar Co stock appears to be undervalued.
The current stock price of 円1,564.00 is trading 8.6% below its estimated GF Value™ of 円1,710.48.
GuruFocus considers Nippon Chemiphar Co to be Fairly Valued.
Key valuation signals for TSE:4539:
Debt-to-EBITDA: 2.35 (66% below median its 10-year median of 7.00)
GF Value™: 円1,710.48 vs. price of 円1,564.00 (8.6% below fair value)
Industry Position: 48.7% above the Drug Manufacturers median (#618 of 685)
No single metric tells the full story. See the TSE:4539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Chemiphar Co Ltd produces and sells medicines for medical use. The company also produces medical, health and cosmetics products. Nippon Chemiphar sterilizes medical instruments for hospitals and operates nursing home for elderly.
50GF Score
Get the complete analysis for TSE:4539
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4539 has been successfully added to your 
